NanoCell Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $10M

  • Investors
  • 6

NanoCell Therapeutics General Information

Description

Developer of in-vivo gene therapies designed to treat oncology and autoimmune diseases. The company's technology leverages a non-viral DNA-based platform and cell-directed lipid nanoparticles to modify immune-effector cells directly within the patient, providing a treatment method that eliminates ex-vivo cell manipulation and improves the scalability and affordability of car-t therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1055 Westlakes Drive
  • 3rd floor
  • Berwyn, PA 19312
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1055 Westlakes Drive
  • 3rd floor
  • Berwyn, PA 19312
  • United States

NanoCell Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NanoCell Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 16-Jun-2025 $10M Completed Generating Revenue
2. Grant 04-Jan-2023 Completed Startup
1. Accelerator/Incubator 01-Jan-2021 Completed Startup
To view NanoCell Therapeutics’s complete valuation and funding history, request access »

NanoCell Therapeutics Patents

NanoCell Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024133600-A1 Integrating and self-inactivating viral vectors and constructs and uses thereof Inactive 20-Dec-2022

NanoCell Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NanoCell Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Institute for Follicular Lymphoma Innovation Not-For-Profit Venture Capital Minority
Imperial College London University
Karolinska Institutet Holding Holding Company
Sintef Corporation
Utrecht University University
You’re viewing 5 of 6 investors. Get the full list »

NanoCell Therapeutics FAQs

  • When was NanoCell Therapeutics founded?

    NanoCell Therapeutics was founded in 2021.

  • Where is NanoCell Therapeutics headquartered?

    NanoCell Therapeutics is headquartered in Berwyn, PA.

  • What is the size of NanoCell Therapeutics?

    NanoCell Therapeutics has 16 total employees.

  • What industry is NanoCell Therapeutics in?

    NanoCell Therapeutics’s primary industry is Drug Discovery.

  • Is NanoCell Therapeutics a private or public company?

    NanoCell Therapeutics is a Private company.

  • What is NanoCell Therapeutics’s current revenue?

    The current revenue for NanoCell Therapeutics is .

  • How much funding has NanoCell Therapeutics raised over time?

    NanoCell Therapeutics has raised $10M.

  • Who are NanoCell Therapeutics’s investors?

    Institute for Follicular Lymphoma Innovation, Imperial College London, Karolinska Institutet Holding, Sintef, and Utrecht University are 5 of 6 investors who have invested in NanoCell Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process